Comparative Study of CA-50 (Time-Resolved Fluoroimmunoassay), Span-1, and CA19-9 in the Diagnosis of Pancreatic Cancer

References

• Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fulner P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957–972
   PubMedGoogle Scholar
• Steinberg W M, Gelfand R, Anderson K K, et al. Comparison of the sensitivity and specificity of the CA19–9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90: 343–349
   PubMed Web of Science ®Google Scholar
• Farini R, Fabris C, Bonvicini P, et al. CA19–9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol 1985; 21: 429–432
   PubMedGoogle Scholar
• San F, Beger H G, Bittner R, Buchler M, Krautzberger W. CA19–9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779–783
   PubMed Web of Science ®Google Scholar
• Domschke W. Selective methodology for a precocious diagnosis of pancreatic cancer. Lecture held at the XVI European Pancreatic Club meeting. September, 12–151985. Foundation for Retrovirology and Human Health, Cascais
   Google Scholar
• Schmiegel W H, Kreiker C, Eberl W, et al. Monoclonal antibody defines CA19–9 in pancreatic juices and sera. Gut 1985; 26: 456–460
   PubMed Web of Science ®Google Scholar
• Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C, Makela O. Comparison of a new tumor marker, CA19–9, with alpha fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37: 218–222
   PubMed Web of Science ®Google Scholar
• Kew M C, Berger E L, Koprowski H. Carbohydrate antigen 19–9 as a serum marker of hepatocellular carcinoma. Comparison with alphafetoprotein. Br J Cancer 1987; 56: 86–88
   PubMed Web of Science ®Google Scholar
• Kawa S, Oguchi H, Tokoo M, et al. A comparative study of the clinical usefulness of CA19–9, CA-50, Sialyl SSEA-1 and Dupan-2 for the diagnosis of pancreatic carcinoma used alone or in combination. Jpn J Clin Chem 1990; 19: 389–398
   Google Scholar
• Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialo-gangliosides. Int Arch Allergy Appl Immunol 1983; 71: 178–181
   PubMedGoogle Scholar
• Mansson J E, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985; 834: 110–117
   PubMed Web of Science ®Google Scholar
• Nilsson O, Manssen J E, Lindholm L, Holmgren J, Svennerholm L. Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett 1985; 182: 398–402
   PubMed Web of Science ®Google Scholar
• Harmenberg U, Wahren B, Wiechel K L. Tumor markers carbohydrate antigens CA19–9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary. Cancer Res 1988; 48: 1985–1988
   PubMed Web of Science ®Google Scholar
• Holmgren J. Tumor marker antigens. Clinical experience with the carbohydrate antigen CA-50 in the serum of carcinoma patients, H D Bruhn, A Everding, B Joos, J Hedderich. Studentlitteratur, Lund 1985; 92–103
   Google Scholar
• Haglund C, Lindgrem J, Roberts P J, Nordling S. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA19–9. Int J Cancer 1986; 38: 841–846
   PubMed Web of Science ®Google Scholar
• Haglund C, Kuusela P, Jalanko H, Roberts P J. Serum CA50 as a tumor marker in pancreatic cancer: a comparison with CA19–9. Int J Cancer 1987; 39: 477–481
   PubMed Web of Science ®Google Scholar
• Masson P, Palsson B, Sandberg A A. CA-50 in patients with pancreatic disease—an evaluation of three different laboratory techniques. Scand J Clin Lab Invest 1988; 48: 751–755
   PubMed Web of Science ®Google Scholar
• Cooper E H, Knowles J C, Parker D, Taylor M. An evaluation of serum CA-50 levels in cancer using a time-resolved fluoroimmunoassay. Biomed Pharmacother 1988; 42: 189–196
   PubMed Web of Science ®Google Scholar
• Koch O M, Demetriades G, Heidi G, Wust G, Hardenbicker C H. Evaluation of a novel fluorometric assay for the determination of CA-50 antigen. J Tumor Marker Oncol 1987; 3: 197–200
   Google Scholar
• Chung Y S, Ho J JL, Kim Y S. Monoclonal antibody reactive with sera of pancreatic cancer patients [Abstract]. Dig Dis Sci 1985; 30: 967
   Web of Science ®Google Scholar
• Chung Y S, Ho J JL, Kim Y S, et al. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987; 60: 1636–1643
   PubMed Web of Science ®Google Scholar
• Ho J JL, Chung Y S, Fujimoto Y, et al. Mucinlike antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies Span-1 and Ypan-1. Cancer Res 1988; 48: 1985–1988
   PubMedGoogle Scholar
• Sowa M, Chung Y S, Nishimura M, et al. An immunohistological study of gastric cancer with special reference to the expression of carbohydrate antigens and nuclear DNA ploidy patterns. Eur J Surg Oncol 1989; 15: 307–315
   PubMedGoogle Scholar
• Kiriyama S, Hayakawa T, Kondo T, et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65: 1557–1561
   PubMed Web of Science ®Google Scholar
• Child C G, Turcotte J G. Surgery and portal hypertension. The liver and portal hypertension, C G Child. W.B Saunders, Philadelphia 1964; 48–55
   Google Scholar
• Malesci A, Tommasini M A, Bonato C, et al. Determination of CA19–9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92: 60–67
   PubMed Web of Science ®Google Scholar
• Sakahara H, Endo K, Nakajima K, et al. Serum CA19–9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57: 1324–1326
   PubMed Web of Science ®Google Scholar
• Pollard H M. Staging of cancer of the pancreas. Cancer of the Pancreas Task Force. Cancer 1981; 47: 1631–1637
   PubMed Web of Science ®Google Scholar
• Reports of registered pancreatic cancer cases in Japan. Cumulative survival rates of patients with pancreatic cancer, Y Saithoh, Annual report of national registration of pancreatic cancer patients in 1988 49in Japanese
   Google Scholar
• Talbot R W, Nagorney D M, Pemberton J H, Wieand H S, Ritts R E, Jr. Comparison of portal and peripheral blood levels of carcinoembryonic antigen, CA19–9, and CA125 tumor-associated antigens in patients with colorectal and pancreatic cancer. Cancer Res 1989; 49: 542–543
   PubMed Web of Science ®Google Scholar